Intelligent Bio Solutions Inc. Common Stock

Intelligent Bio Solutions Inc. (INBS) closed a $10.0 million private placement with two healthcare-focused institutional investors, issuing 2,298,850 shares of common stock at $4.35 per share along with Series K-1 and K-2 warrants. The company plans to use proceeds for working capital, FDA 510(k) submission for its Intelligent Fingerprinting Drug...

U.S. stock futures rose on the first trading day of 2026, with the S&P 500 and Nasdaq 100 gaining in premarket trading. Key movers included Baidu jumping 12.2% on a spinoff announcement, Rubico surging 16.8% following an acquisition deal, while Outlook Therapeutics plummeted 56.5% after an FDA rejection and Intelligent Bio Solutions dropped 23.4%...

Intelligent Bio Solutions Inc. (INBS) announced a $10.0 million private placement of 2,298,850 shares of common stock and warrants priced at $4.35 per share to two healthcare-focused institutional investors. The company plans to use net proceeds for working capital and general corporate purposes. Closing is expected on or about January 2, 2026, w...

Intelligent Bio Solutions Inc. (INBS) announced plans to upgrade its Intelligent Fingerprinting Drug Screening System to support multiple languages, making it accessible to over 4 billion users worldwide. This move aligns with the company's strategic global expansion goals, including a planned entry into the US market in 2025.

Intelligent Bio Solutions Inc. (INBS) announced that Quantum Traffic Management (Quantum TM), a UK-based traffic management provider, has adopted INBS' Intelligent Fingerprinting Drug Testing Solution across its 10 nationwide sites. The fingerprint-based system enables Quantum TM to conduct on-the-spot drug screening in-house, improving testing e...